Antithrombotic Activity of NSP-513, a Novel Selective Phosphodiesterase 3 Inhibitor, on Femoral Arterial Thrombosis Induced by Physical Stenosis and Electrical Current: Comparison of Antithrombotic and Hemodynamic Effects
Authors:
- Satoshi MashikoSMSatoshi Mashiko
- Toshifumi KimuraTKToshifumi Kimura
- Fumiaki IshidaFIFumiaki Ishida
- Nobuo MochizukiNMNobuo Mochizuki
- Tadayuki NishibeTNTadayuki Nishibe
- Masaru NishikibeMNMasaru Nishikibe
- 1 April 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 35 (4) , 586-594
Abstract
NSP-513, a novel potent and selective phosphodiesterase 3 (PDE 3) inhibitor, and cilostazol, a previously developed PDE 3 inhibitor, were compared with respect to antiplatelet, antithrombotic, and hemodynamic effects. In the in vitro antiplatelet aggregation studies, NSP-513 and cilostazol inhibited collagen-induced canine platelet aggregation with median inhibitory concentration (IC50) values of 0.093 and 3.1 μM, respectively, and inhibited adenosine diphosphate (ADP)-induced canine platelet aggregation with IC50 values of 0.15 and 12 μM, respectively. For ADP-induced platelet aggregation, the presence of prostaglandin E1 (PGE1; 3 and 10 nM) further decreased the IC50 values for NSP-513 to 0.11 and 0.032 μM, respectively. In ex vivo antiplatelet aggregation studies, orally administered NSP-513 (0.03-1 mg/kg) and cilostazol (50 mg/kg) inhibited collagen-induced canine platelet aggregation. In an in vivo canine femoral arterial thrombosis model, intraduodenally administered NSP-513 (0.01-0.03 mg/kg) dose-dependently prevented thrombus formation without any changes in blood pressure, heart rate, or bleeding time. In conscious dogs, NSP-513 at oral doses of ≥0.3 mg/kg produced hemodynamic changes such as decreased blood pressure and increased heart rate and LVdP/dtmax. Thus the minimal hemodynamically effective dose of NSP-513 was 0.3 mg/kg, and the hemodynamic effects of this dose were comparable to those of 50 mg/kg of cilostazol. In conclusion, these data suggest that NSP-513 has in vivo selectivity for antiplatelet and antithrombotic activities over hemodynamic activity, and that the selectivity of NSP-513 is higher than that of cilostazol in dogs.Keywords
This publication has 25 references indexed in Scilit:
- Antiplatelet and Antithrombotic Effects of a Novel Selective Phosphodiesterase 3 Inhibitor, NSP-513, in Mice and RatsThe Japanese Journal of Pharmacology, 2000
- CilostazolCardiovascular Drug Reviews, 1993
- Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymesTrends in Pharmacological Sciences, 1991
- Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipramNaunyn-Schmiedeberg's Archives of Pharmacology, 1990
- Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitorsTrends in Pharmacological Sciences, 1990
- Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human plateletsBiochemical Pharmacology, 1988
- Cyclic nucleotide phosphodiesterase inhibitors prevent aggregation of human platelets by raising cyclic amp and reducing cytoplasmic free calcium mobilizationThrombosis Research, 1987
- Selective inhibitors of three forms of cyclic nucleotide phosphodiesterasesTrends in Pharmacological Sciences, 1984
- Tissue and substrate specificity of inhibition by alkoxy-aryl-lactams of platelet and arterial smooth muscle cyclic nucleotide phosphodiesterases relationship to pharmacological activityBiochemical and Biophysical Research Communications, 1983
- Aggregation of Blood Platelets by Adenosine Diphosphate and its ReversalNature, 1962